Biogen

This study tests a drug called felzartamab in 120 kidney transplant patients whose bodies are attacking their new kidney (antibody-mediated rejection). The drug targets immune cells that make harmful antibodies, aiming to stop damage and keep the kidney working. Participants will…

This study tests an experimental drug called litifilimab for people with active lupus skin disease (subacute or chronic cutaneous lupus) who didn't get better with standard antimalarial therapy. About 450 participants will receive either the drug or a placebo for 24 weeks, then a…

This study tests a drug called felzartamab in 81 kidney transplant recipients who developed microvascular inflammation (MVI), a type of blood vessel injury that can lead to kidney failure. There are no approved treatments for this condition. Participants will receive either felza…

This study tests a drug called felzartamab in people with IgA nephropathy, a kidney disease where abnormal antibodies build up and damage the kidneys. The goal is to see if felzartamab can lower the amount of protein in urine, a sign of kidney damage. About 454 adults will receiv…

This study tests a new drug called salanersen for people aged 15 to 60 with spinal muscular atrophy (SMA). The drug aims to help the body produce more of a key protein needed for muscle and nerve function. Participants receive one injection into the spinal fluid each year for 5 y…

This study tests a new drug, felzartamab, for people with primary membranous nephropathy (PMN), a kidney disease where the body's immune system attacks the kidneys. The goal is to see if felzartamab can lower protein in the urine and protect kidney function better than the curren…

This study tests a drug called omaveloxolone (SKYCLARYS) in children aged 2 to 15 with Friedreich's ataxia, a rare nerve disease that affects movement and balance. The drug is already approved for people 16 and older. In the first year, some children get the drug and some get a p…

This study checks the long-term safety of tofersen (Qalsody) in 12 Chinese adults with a specific genetic type of ALS (SOD1-ALS). Participants receive 13 doses injected into the spine over a year. The main goal is to track side effects and how the drug moves through the body.

This study tests a drug called salanersen in babies who have a genetic diagnosis of spinal muscular atrophy (SMA) but no symptoms yet. The drug aims to help the body make more of a protein needed for muscle and nerve function. Researchers want to see if early treatment can help b…

This study looks at how the body handles nusinersen (Spinraza) when given through a new implanted device called ThecaFlex DRx™, compared to a standard lumbar puncture. About 58 people with spinal muscular atrophy who are already in the PIERRE study will take part. Researchers wil…

This study tests an approved FA drug (omaveloxolone) in 35 children aged 2 to 15 to see how their bodies process it and whether it is safe. The drug is already available for patients 16 and older. Researchers will monitor side effects, growth, and heart health over up to 240 week…

This study looks at the long-term safety of the drug tofersen (Qalsody) in people with a rare, inherited form of ALS called SOD1-ALS. Researchers will collect health information from about 125 participants in Europe and the U.S. over at least 7 years, without changing their medic…

This study collects health information from pregnant women with spinal muscular atrophy (SMA) who have taken the drug Spinraza (nusinersen). Researchers want to learn about pregnancy outcomes and baby health, since little is known about the drug's effects during pregnancy. About …

This early-phase study tests the safety of a new drug called BIIB145, which is being developed for multiple sclerosis (MS). Since this is the first time the drug is given to people, it involves 104 healthy adults to see how the body handles it and if it causes any side effects. P…

This study follows about 1,178 pregnant women with multiple sclerosis to see if taking the drug diroximel fumarate (VUMERITY®) affects their babies. Researchers will compare birth outcomes among women who took the drug, those who took other MS drugs, and those who took no MS drug…

This observational study follows 300 people with Friedreich's ataxia who are taking the prescribed drug omaveloxolone (SKYCLARYS®). Researchers will collect safety information from routine doctor visits over up to 5 years. The goal is to monitor serious side effects, especially h…

This early-stage study is testing the safety of a new drug called BIIB142 in healthy adults. Researchers want to see how the body handles the drug and what side effects may occur. The study involves giving single or multiple doses to different groups and comparing them to a place…

This study tests whether a new tablet form of the drug omaveloxolone (BIIB141) that dissolves in liquid works the same in the body as the current capsule form. The study involves 70 healthy adults who will take both forms at different times. The goal is to see if the liquid table…

This study follows 200 people with postpartum depression who are prescribed zuranolone. Participants complete online surveys about their symptoms before starting the drug and again at 15, 45, and 90 days. The goal is to see how symptoms change over time in real-world use, not to …